Emcure Pharmaceuticals Limited (EMCURE.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,875.00 (+5.33%) as of
Key statistics
- Market cap
- 355.71B
- P/E (TTM)
- 35.34
- Forward P/E
- 24.12
- EPS (TTM)
- 53.06
- Dividend yield
- 0.20%
- 52-week range
- 1,306.50 – 2,100.70
- Beta
- -0.08
- Revenue (TTM)
- 96.83B
- Profit margin
- 10.44%
- Analyst target
- ₹2,229.38
- Volume
- 83.84k
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Pune, India
- Employees
- 6,914
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.